Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MG4101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| The Control Group | NO_INTERVENTION | Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment. |
| The Treatment Group (MG4101) | EXPERIMENTAL | Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7. |
| Name | Type | Description |
|---|---|---|
| MG4101 | BIOLOGICAL | MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions. |
Inclusion criteria 1. Patients who are between 20 to 80 years of age 2. Life expectancy \> 12 weeks 3. Patients have complete remission according to the mRECIST by Dynamic contrast-enhanced 3- or 4-phase CT or tissue biopsy * Patients were diagnosed Hepatocellular Carcinoma BCLC stage B be-fore...
MG4101 is an investigational allogeneic natural killer cell therapy being studied for the treatment of intermediate-stage hepatocellular carcinoma, a type of liver cancer. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
MG4101 is a monoclonal antibody-based therapy that utilizes allogeneic natural killer cells. Its mechanism involves the use of donor-derived natural killer cells to target and attack cancer cells, though the specific molecular target is not disclosed in the available clinical trial information.
MG4101 is being developed by Artiva Biotherapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ARTV on the stock market.
MG4101 is currently in Phase 2 clinical development. It has completed one Phase 2 clinical trial, and the drug remains investigational, meaning it has not received approval from regulatory agencies such as the FDA.
MG4101 has been studied in a completed Phase 2 clinical trial with the identifier NCT02854839. This trial, titled 'A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma,' enrolled 78 participants in South Korea and included adults aged 18 years and older.
MG4101 is a specific allogeneic natural killer cell therapy developed by Artiva Biotherapeutics. It is not known to be the same as other natural killer cell therapies, as no alternative names have been reported for this investigational drug.